Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mvabea
- Development stage
- Phase 3
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Mvabea (MVA-BN-Filo) is a recombinant, non-replicating, multivalent viral vector vaccine based on the Modified Vaccinia Ankara (MVA) platform. It encodes glycoproteins from Zaire ebolavirus (Mayinga variant), Sudan ebolavirus (Gulu variant), Taï Forest ebolavirus nucleoprotein, and Marburg marburgvirus (Musoke variant). The encoded proteins are expressed locally after administration and stimulate an immune response against these filoviruses. The primary indication is the prevention of Ebola virus disease caused by Zaire ebolavirus in adults and children aged one year or older. It is administered as part of a two-dose regimen with Zabdeno for individuals at risk of infection[1][2][4].
- Brand names
- Mvabea
- Other names
- Ebola Marburg virus vaccine - Bavarian NordicMarburg Ebola virus vaccine - Bavarian Nordic
02
Targets
PYG (Glycogen phosphorylase)Zaire ebolavirus glycoproteinNP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on Mvabea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mvabea.